– Data from ATH434-201 double-blind Phase 2 trial to be featured in oral session and multiple poster presentations – MELBOURNE, Australia and SAN FRANCISCO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that data from the ATH434-201 randomized, double-blind Phase 2 clinical trial in Multiple System Atrop

SANTA CLARA, Calif., Oct. 2, 2025 /PRNewswire/ -- AIxMed Inc., a leader in computational cytology and AI-powered diagnostics, and Biopticka Laboratoř s.r.o., the Czech Republic's leading private reference laboratory, today announced the signing of a Memorandum of Understanding (MOU) to integrate AIxURO™ into their laboratory system. AIxURO™ is AIxMed's proprietary AI-powered solution for urine cytology. AIxURO™ is designed to support urine cytology workflows using The Paris System for Reporting

ANAVEX3-71-SZ-001 achieved its primary endpoint demonstrating safety and tolerability in adults with schizophrenia Encouraging trends observed in biomarkers support continued development NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, today announced posi

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Michigan-based manufacturer Hans Scien tific is investing $2 billion in the US due to President Donald Trump’s threat last Thursday of 100% pharma tariffs. The expansion includes seven already-planned new builds, with one of the sites already completed, the company said in a Tuesday press release. Thermo Fisher Scientific and Vaxcyt e have inked a commercial manufac

The federal government’s ongoing shutdown means that the FDA can’t accept new drug or biologic submissions that require a user fee. But it may not change this year’s pace of applications — yet. While Democrats and Republicans have yet to work out a deal for funding the government , companies including Moderna, Viridian Therapeutics, Cogent Biosciences and Avidity Biosciences told Endpoints News that the shutdown isn’t expected to affect their upcoming filings, all of which are planned before the

SINGAPORE, Oct. 02, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, is pleased to announce the publication of a preclinical study, in a research article entitled “Donor-Derived Vγ9Vδ2 T

ROCKVILLE, Md., Oct. 2, 2025 /PRNewswire/ -- OncoC4, Inc. a clinical-stage biotechnology company, today announced the recent closing of a Series B financing round of nearly $50 million. The round was led by GBA Fund, and supported by additional capital from the Company's co-founders and existing investors, including HM Capital, 3E Bioventures Capital and Kaitai Capital. OncoC4 was founded in 2020 by two renowned immunologists and serial entrepreneurs, Dr. Yang Liu and Dr. Pan Zheng. By leveragin

DT-101 is designed to allow effective modulation of the AMPA receptor without compromising safetyPhase 2 clinical trial initiation anticipated before the end of 2025Trial builds on positive Phase 1 study that showed DT-101 was well tolerated and demonstrated target engagement Cardiff, United Kingdom – 2 October 2025 – Draig Therapeutics (“Draig”), a clinical-stage company aiming to transform the treatment of neuropsychiatric diseases, today announces that it will initiate a Phase 2 study of DT-

As biotech IPOs hit a record low in the US, more than 40 Chinese biopharma companies have filed to go public so far this year. That’s more than four times the number that have sought a Nasdaq or New York Stock Exchange listing. It’s the latest signal of China’s booming biotech scene, which is increasingly viewed as a go-to place for Western startups and large drugmakers to license or buy new medicines at a time when the biotech sector has stalled in the US. In the first three quarters of 2025, a

Highlights: US Tariffs: Immuron does not anticipate any material impact from the recently announced US tariffs on pharmaceutical productsTravelan® Clinical Study: Topline results from the Travelan® clinical study conducted by Uniformed Services University are anticipated in October 2025 IMM-529 Regulatory Milestone: Immuron plans to submit an Investigational New Drug (IND) application to the U.S. FDA for IMM-529 (Clostridiodes difficile infection) in mid-October 2025ProIBS® Commercial Launch: T